Transgenic mouse expressing human TTR Ile84Ser mutation and cynomolgus monkey (TTR mRNA/protein lowering)
“In vitro (human and monkey hepatocytes) and in vivo (monkey and transgenic mouse expressing the human TTR Ile84Ser mutation) studies documented decreases in TTR mRNA and protein levels following repeat-dose subcutaneous (SC) administration of inotersen.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Why that model
Target sequence conserved in monkey; 8 mismatches in rodents and 4 in rabbits
“The target sequence of inotersen is conserved between monkeys and humans, but contains 8 mismatches in rodents and 4 mismatches in rabbits.”
EMA: proof of concept adequately demonstrated in human/monkey hepatic cells, monkeys and mutant human TTR transgenic mice
““Proof-of-concept” of the pharmacodynamic activity of inotersen was adequately demonstrated by the inhibition of TTR mRNA translation in hepatic cells of humans and monkeys in vitro as well as in monkeys and in transgenic mice overexpressing a mutated human TTR variant in vivo.”